A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Status:
Completed
Trial end date:
2021-10-12
Target enrollment:
Participant gender:
Summary
Plaque psoriasis is a chronic relapsing inflammatory skin disease that is characterized by
keratinocyte hyper-proliferation and epidermal hyperplasia. Standard treatment for psoriasis
generally requires long-term use of topical therapies, psoralen and ultraviolet A (PUVA),
ultraviolet B (UVB) and/or systemic immunosuppressant therapies to achieve and maintain
adequate disease control. This is a multicenter, randomized, double-blind study conducted in
participants with moderate to severe plaque psoriasis. The study will evaluate the efficacy,
safety, pharmacokinetic and pharmacodynamics profile of 960 milligram (mg) GSK2982772
administered as a once daily modified release (MR) formulation. Participants will be
randomized in a 2:1 ratio to receive either 960 mg GSK2982772 or placebo for 12 weeks. The
duration of the study, including Screening and follow-up, will be approximately 21 weeks for
each participant.